---
title: "Weekly Recap | Pfizer -1.7%, Blackstone backs GLP-1 push"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305537118.md"
description: "Pfizer (PFE) fell 1.7% this week to close at $28.89, while the S&P 500 gained 2.51%, leaving the stock about 4.21 percentage points behind the benchmark. The week was front-loaded: Monday opened at $29.59 and closed at $29.23, with Tuesday and Wednesday edging up to $29.36 and $29.45. Thursday, 12 November, opened at $29.746 but faded to close at $28.83, and Friday, 13 November, slid further to a weekly low of $28.62 before settling at $28.89. Weekly amplitude was 3."
datetime: "2026-11-14T06:52:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305537118.md)
  - [en](https://longbridge.com/en/news/305537118.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305537118.md)
generator: "portal-rs"
---

# Weekly Recap | Pfizer -1.7%, Blackstone backs GLP-1 push

## The Week

Pfizer (PFE) fell 1.7% this week to close at $28.89, while the S&P 500 gained 2.51%, leaving the stock about 4.21 percentage points behind the benchmark. The week was front-loaded: Monday opened at $29.59 and closed at $29.23, with Tuesday and Wednesday edging up to $29.36 and $29.45. Thursday, 12 November, opened at $29.746 but faded to close at $28.83, and Friday, 13 November, slid further to a weekly low of $28.62 before settling at $28.89. Weekly amplitude was 3.89%, with trading volume roughly in line with the 60-day median. The stock sits below its 20-day moving average of $29.793 but above the 60-day average of $28.73.

## Key Events

The main thread this week was the obesity (GLP-1) pipeline and portfolio adjustments. On Wednesday, 11 November, Pfizer and Blackstone Life Sciences announced a strategic funding agreement under which Blackstone is backing Pfizer’s obesity programme with a $1.5bn fund in exchange for a slice of future sales. A day earlier, CEO Albert Bourla joined the Jefferies Healthcare Conference, saying Pfizer still believes it can lead the GLP-1 market even though its drug may not arrive until 2028.

Alongside the GLP-1 push came an exit decision: on Friday, 13 November, Pfizer confirmed it will stop selling Premarin, a menopause hormone therapy, in Canada. A separate global development surfaced on Saturday, 14 November, after the trading week had ended, with the news that Pfizer and Innovent’s GLP-1 drugs were added to China’s national insurance for diabetes treatment.

## Analyst Ratings

Across 28 institutions covering Pfizer, 8 rate it buy, 1 overweight, 17 hold, 1 underweight and 1 sell. The consensus rating is hold, with a consensus target of $30.22115, about 4.6% above the current price of $28.89. The target range is wide—$37 at the top and $25 at the bottom, a $12 gap—pointing to clear dispersion among analysts. Within the pharmaceutical sector’s 208 covered names, Pfizer ranks third by analyst rating.

## The Week Ahead

The coming week is heavy on US macro data. Monday, 16 November, brings the New York Fed manufacturing index, where consensus expects a drop from the prior 25.5 to 18. Tuesday, 17 November, is the busy day, with retail sales, retail sales ex-autos, industrial production and the NAHB housing market index all due. For Pfizer itself, the next major corporate event sits further out: the FY2026 annual results on 2 February 2027, due pre-market, with consensus estimates of $1.5433 EPS and $63.1bn revenue. The GLP-1 funding deal and the Canada product exit may also see follow-up disclosures worth tracking.

## In Short

Pfizer underperformed the market this week, but the news flow carried weight: the $1.5bn Blackstone commitment keeps the GLP-1 narrative moving, while the Premarin exit from Canada and the China insurance inclusion for the Innovent GLP-1 drug signal continued repositioning of the portfolio. Analysts remain at ‘hold’, and although the consensus target implies about 4.6% upside, the $12 gap between high and low targets reflects uncertainty about the earnings path. On valuation, the latest P/E sits around 40.8x and P/B around 1.85x—not obviously cheap. The question going forward is whether the GLP-1 collaboration yields clearer clinical progress, and how retail and industrial data shape broader risk appetite.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies](https://longbridge.com/en/news/306119677.md)
- [Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund](https://longbridge.com/en/news/305354338.md)
- [Should Long Term Sales Outlook Require Action From Novartis (SWX:NOVN) Investors?](https://longbridge.com/en/news/306371892.md)
- [Thermo Fisher Scientific (TMO) Beat Estimates And Launched VaxEvo, Is An 11% Discount Enough?](https://longbridge.com/en/news/306371979.md)
- [FlatRx Publishes a Dated Price Comparison of Compounded Tirzepatide at 27 U.S. Telehealth Programs Counted at a 10 mg Weekly Dose](https://longbridge.com/en/news/306369437.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**